These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 23283289

  • 61. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
    Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, Yan WH, Shen YP.
    Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
    [Abstract] [Full Text] [Related]

  • 62. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E.
    Am J Ther; 2016 Mar; 23(6):e1293-e1299. PubMed ID: 25611359
    [Abstract] [Full Text] [Related]

  • 63. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate.
    Lee MS, An SY, Jang GC, Kim DS.
    Yonsei Med J; 2002 Aug; 43(4):527-32. PubMed ID: 12205742
    [Abstract] [Full Text] [Related]

  • 64. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
    Kobayashi T, Inoue Y, Morikawa A.
    Nihon Rinsho; 2008 Feb; 66(2):332-7. PubMed ID: 18260333
    [Abstract] [Full Text] [Related]

  • 65. Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease.
    Nakada T.
    Pediatr Cardiol; 2015 Feb; 36(2):335-9. PubMed ID: 25158631
    [Abstract] [Full Text] [Related]

  • 66. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS, Durán DG, Peracaula CS, Iznardi CR, Tardío JO.
    An Pediatr (Barc); 2010 Nov; 73(5):268-71. PubMed ID: 20678974
    [Abstract] [Full Text] [Related]

  • 67. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
    Jaggi P, Wang W, Dvorchik I, Printz B, Berry E, Kovalchin JP, Texter K, Ramilo O, Burns JC, Tremoulet AH.
    Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
    [Abstract] [Full Text] [Related]

  • 68. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 69. Kawasaki disease. The mystery continues.
    Bradley DJ, Glodé MP.
    West J Med; 1998 Jan; 168(1):23-9. PubMed ID: 9448484
    [Abstract] [Full Text] [Related]

  • 70. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.
    Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
    [Abstract] [Full Text] [Related]

  • 71. Kawasaki Disease.
    Son MBF, Newburger JW.
    Pediatr Rev; 2018 Feb; 39(2):78-90. PubMed ID: 29437127
    [No Abstract] [Full Text] [Related]

  • 72. Kawasaki disease in East Mazandaran, Islamic Republic of Iran, 1997-2002.
    Saffar MJ, Reshidighader F.
    East Mediterr Health J; 2005 Feb; 11(1-2):28-35. PubMed ID: 16532668
    [Abstract] [Full Text] [Related]

  • 73. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 74. Initial intravenous gammaglobulin treatment failure in Kawasaki disease.
    Wallace CA, French JW, Kahn SJ, Sherry DD.
    Pediatrics; 2000 Jun 27; 105(6):E78. PubMed ID: 10835091
    [Abstract] [Full Text] [Related]

  • 75. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
    O'connor MJ, Saulsbury FT.
    Clin Pediatr (Phila); 2007 May 27; 46(4):345-8. PubMed ID: 17475994
    [Abstract] [Full Text] [Related]

  • 76. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
    Clin Exp Rheumatol; 2017 May 27; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [Abstract] [Full Text] [Related]

  • 77. Immunoglobulin-resistant Kawasaki disease.
    Marriaga-Núñez B, Arellano-Valdez A, Paz JPA, Bonal-Pérez MA, Montaño-Durón JG, Solórzano-Santos F.
    Bol Med Hosp Infant Mex; 2023 May 27; 80(4):260-264. PubMed ID: 37703575
    [Abstract] [Full Text] [Related]

  • 78. An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes.
    Yim D, Curtis N, Cheung M, Burgner D.
    J Paediatr Child Health; 2013 Aug 27; 49(8):614-23. PubMed ID: 23647873
    [Abstract] [Full Text] [Related]

  • 79. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT.
    Clin Pediatr (Phila); 2002 Oct 27; 41(8):597-601. PubMed ID: 12403377
    [Abstract] [Full Text] [Related]

  • 80. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.
    Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S, Nonoyama S.
    Circulation; 2011 Dec 20; 124(25):2822-8. PubMed ID: 22104548
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.